Monitoring whole blood concentrations of cyclosporin is an important part of treatment since its toxic:therapeutic ratio is very low. Also, the variable pharmacokinetics of cyclosporin among patients make accurate prediction of the initial dosage difficult. This variability results from differences in the drug's absorption, distribution, and clearance.
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volume of distribution may be altered in patients with liver or renal disease.
range of other conditions, including Another important aspect in its distribution is that it is highly bound to psoriasis, rheumatoid arthritis, and erythrocytes and plasma lipoproteins. At low blood concentrations (below asthma 80 nmolIl (100 ng/ml)) and when the packed cell volume is low (for example, in patients with kidney failure) the contribution of the plasma bound fraction becomes more important to the disposition of the drug.
Cyclosporin is metabolised in the liver and its clearance may therefore be reduced in patients with liver disease. Both cyclosporin and its metabolites are excreted in bile and little cyclosporin appears in the urine. Thus We will now apply to cyclosporin the criteria which must be fulfilled in part or in full before the measurement of its plasma concentration in organ transplantation can be considered worth while.
Is there difficulty in interpreting clinical evidence ofthe therapeutic or toxic effects?
Information about the relation between blood concentrations of cyclosporin and its therapeutic effects is largely limited to its use in preventing the rejection of transplanted organs, although information about toxicity may relate to all of its clinical uses.
During the early stages after organ transplantation, when the risk of rejection is high, detecting evidence of rejection can be difficult, and since prediction of blood cyclosporin concentrations is limited by the enormous variability in the drug's kinetics, at this stage their measurement may be of use in determining an effective dose and in minimising the risk of toxicity. In the later stages, when the risk of rejection is lower and organ function tests better reflect the risk of rejection, measurements are needed less often.
In the special case of kidney transplantation, however, it may be impossible at every stage to use renal function tests to distinguish between an episode of transplant rejection on the one hand and cyclosporin induced renal damage on the other. In these cases measuring the blood cyclosporin concentration may be of value.
Is there a good relation between the blood concentration and its therapeutic or toxic effects?
In individual studies the therapeutic effects of cyclosporin correlate quite well with its effects in suppressing acute transplant rejection. However, when different studies are compared there is a wide variation in the cyclosporin concentration above which the risk of transplant rejection is increased. This variation in the relation between effect and concentration is largely due to differences between assay methods, although there may also be differences attributable to the time after transplantation.
If one of the more specific assay methods for cyclosporin is used (such as high performance liquid chromatography or a specific radioimmunoassay based on a monoclonal antibody) the risk of transplant rejection in the first six months seems to be increased when the trough whole blood cyclosporin concentration is below 80-200 nmolIl (100-250 ng/ml), depending on the laboratory. After six months lower concentrations may be compatible with maintained efficacy.
There is little information on the relation between the therapeutic response in psoriasis and the whole blood cyclosporin concentration, but there is some evidence that the two are not well related.
The risk of toxic effects increases with whole blood cyclosporin concentration, although there is a great deal of overlap with therapeutic concentrations. The risks of nephrotoxicity, hepatotoxicity, and other adverse effects increase at whole blood cyclosporin concentrations above 170-330 nmol/l (200-400 ng/ml), depending on the laboratory. Because the pharmacokinetics of cyclosporin may be subject to some diurnal variation the blood sample should be taken at the same time of day in each patient. This is most simply done before the morning dose, whether the patient is taking cyclosporin once or twice daily. 
